NDM-CRE Cases Surge Nationwide
The Centers for Disease Control and Prevention (CDC) has identified a sharp increase in infections caused by New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE) across the United States. From 2019 to 2023, the number of reported cases climbed by more than 460%. These infections, which can affect the bloodstream, lungs, urinary tract, and wounds, are highly resistant to standard treatments and can be fatal.
Detection and Treatment Remain Difficult
NDM-CRE infections are particularly challenging to detect due to limited testing in laboratories, delaying diagnosis and treatment. The bacteria’s resistance to powerful antibiotics makes managing infections complex, increasing the risk of severe illness or death. Health authorities stress the importance of timely identification and strict infection control measures to prevent further spread.
Growing Public Health Concern
The surge in NDM-CRE contributes to the broader problem of antibiotic-resistant infections in the U.S., which continue to cause thousands of cases and deaths each year. Experts highlight the urgent need for improved diagnostic methods, greater public awareness, and the development of new therapies to combat this escalating threat.
